AgingResearch.News
Hepatology International

Comparative risk of hepatocellular carcinoma and mortality among initiators of GLP-1 receptor agonists versus other glucose-lowering therapies: a target trial emulation

By Jesús Gibran Hernández-Pérez, Omer Abdelgadir, Subin Jang, Show 7 more authorsDavid S. Lopez
Cohort study in peopleInterventions

5 years

Paper

The paper

Jesús Gibran Hernández-Pérez, Omer Abdelgadir, Subin Jang, Show 7 more authorsDavid S. Lopez

Instituto Nacional de Salud Pública; Harold C. Simmons Comprehensive Cancer Center

Hepatology International, 12 Aug 2026

doi.org/10.1007/s12072-026-11138-9PubMed 42584814

More on GLP-1 receptor agonists